Atterocor said Wednesday that it has beefed up its clinical advisory board with eight additions. Among them are Dr. Wiebke Arlt and Dr. Eric Baudin. Based in Ann Arbor, Michigan, Atterocor is a company that is focused on treating adrenal cancer. Its backers include Frazier Healthcare, Osage University Partners and 5AM Ventures.
ANN ARBOR, Mich.–(BUSINESS WIRE)–Atterocor, Inc., a company developing a novel therapy for adrenal cancer, today announced the appointment of eight leading experts to its newly founded clinical advisory board. Atterocor convened the inaugural meeting of its clinical advisory board in conjunction with the 12th Annual European Network for the Study of Adrenal Tumours (ENS@T) Scientific Meeting, which was held Nov. 22-23, 2013 in Budapest. Atterocor is a supporting member of ENS@T.
“Atterocor has established a clinical advisory board that brings together leading adrenal cancer researchers and clinicians from around the world,” said Julia C. Owens, Ph.D., president and chief executive officer of Atterocor. “These advisers will serve an important role in working with Atterocor to guide the accelerated development of ATR-101, which recently entered a Phase 1 clinical study in patients with advanced adrenocortical carcinoma. We look forward to collaborating with our clinical advisers to advance a potential new treatment for patients suffering from this extremely rare disease for which there are limited therapeutic options.”
Atterocor’s inaugural clinical advisory board members include:
Wiebke Arlt, M.D., D.Sc., professor of medicine and head of the Centre for Endocrinology, Diabetes and Metabolism at the University of Birmingham, UK; consultant endocrinologist at the University Hospital Birmingham, the Birmingham Women’s Hospital and the Birmingham Children’s Hospital. Dr. Arlt is a committed clinician scientist and heads a large research group working on basic and clinical aspects of adrenal and gonadal disorders.
Eric Baudin, M.D., Ph.D., principal investigator of the Institut Gustave Roussy (Paris), a cancer center recognized in France as the unique center of excellence for all endocrine tumors, including thyroid, adrenals and neuroendocrine, by the National Institute of Cancer.
Jérôme Bertherat, M.D., Ph.D., professor of endocrinology at Paris Descartes University; head of the Center for Rare Adrenal Diseases at Cochin Hospital in Paris; member of the executive committee and treasurer of ENS@T; and deputy chief editor of the European Journal of Endocrinology. Dr. Bertherat’s main research specialties include endocrine tumors, the genetics of familial endocrine tumors and Cushing’s syndrome.
Felix Beuschlein, M.D., head of endocrine research at the Medizinische Klinik IV, Ludwig-Maximilians University in Munich; vice president of the German Endocrine Society; and chairman of ENS@T. Dr. Beuschlein’s research specialties include adrenal physiology and pathophysiology, endocrine hypertension and stress research.
Martin Fassnacht, M.D., professor for medicine and endocrinology at the Ludwig-Maximilian University of Munich and head of clinical endocrinology for the Center for Endocrine Tumors at the University Hospital Munich. Dr. Fassnacht is a clinical scientist with a special focus on adrenal diseases and endocrine oncology. His research aims at a better understanding of the pathogenesis of adrenal tumors and new treatment strategies for adrenocortical carcinoma.
Mouhammed Amir Habra, M.D., assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center. Dr. Habra is an oncologic endocrinologist whose clinical practice focuses on endocrine tumors and endocrine complications in cancer patients, with special interest in adrenal and thyroid tumors.
Gary Hammer, M.D., Ph.D., Atterocor co-founder; Millie Schembechler Professor of Adrenal Cancer, director of the Endocrine Oncology Program and director of the Center for Organogenesis at the University of Michigan. Dr. Hammer is a medical endocrinologist specializing in the treatment of adrenal diseases.
Massimo Terzolo, M.D., associate professor of internal medicine and director of the Division of Internal Medicine at the San Luigi Hospital, University of Turin in Italy. Dr. Terzolo’s research specialties include adrenocortical tumors, Cushing’s syndrome and acromegaly, and he has been the coordinator of many Italian multicenter studies on adrenal tumors.
About Adrenal Cancer
Adrenal cancer is often diagnosed in the late stages of disease when there is a very poor patient prognosis. Adrenocortical carcinoma (ACC) is a cancer of the adrenal cortex that occurs when cancer cells form in the outer layer (cortex) of the adrenal gland. This form of cancer is rare, with approximately 500 to 600 patients diagnosed in the U.S. each year and around 1,000 patients in the U.S. overall. Current treatment options are often toxic, ineffective and poorly tolerated in many patients, and surgery is not a viable treatment option for the majority of ACC patients. With limited treatment options, there exists a desperate need for new therapies for adrenal cancer.
About Atterocor, Inc.
Atterocor is focused on the development of ATR-101, a novel, oral drug candidate for the treatment of adrenocortical carcinoma (ACC). Founded in 2012, Atterocor is backed by $16 million in Series A venture capital financing from top-tier life sciences investors Frazier Healthcare, Osage University Partners and 5AM Ventures, along with the Regents of the University of Michigan under the MINTS program (Michigan Investment in New Technology Startups) and The Michigan Pre-Seed Capital Fund, an MEDC program managed by Ann Arbor Spark. Atterocor is based in Ann Arbor, Michigan.